Paper17876013
Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study.
Saltz LB and 11 others. J Clin Oncol, 2007. Cited by 371 papers, by iCite.
Cite this record
ConductScience Library. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. Papers, record 17876013. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17876013
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study.
- PubMed
- Publication types
- Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural
- PubMed
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibodies, Monoclonal | Major topic |
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Camptothecin | Major topic |
| Colorectal Neoplasms | Major topic |
| Adult | |
| Aged | |
| Aged, 80 and over | |
| Antibodies, Monoclonal, Humanized | |
| Bevacizumab | |
| Cetuximab | |
| Disease Progression | |
| Female | |
| Humans | |
| Irinotecan | |
| Male | |
| Middle Aged | |
| Neoplasm Metastasis | |
| Treatment Outcome |
Source PubMed
Grants5
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| N01-CM-07003-CM74S | NCI NIH HHS | United States | PubMed | |
| N01-CM-17003 | NCI NIH HHS | United States | PubMed | |
| N01-CM-17102 | NCI NIH HHS | United States | PubMed | |
| N01-CM17101 | NCI NIH HHS | United States | PubMed | |
| N01-CM17105 | NCI NIH HHS | United States | PubMed |
Source PubMed
Comments and corrections2
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 17876011 | Combined antiangiogenesis and antiepidermal growth factor receptor targeting in the treatment of cancer: hold back, we are not there yet. | https://conductscience.org/library/papers/17876011 | PubMed |
| Comment in | 18202430 | Bevacizumab: one treatment for all the seasons? | https://conductscience.org/library/papers/18202430 | PubMed |
Cited by164
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 371 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42321955 | Studying When to Add Biological Therapy to Cytotoxic Therapy in Advanced Cancer Care Using Real World Data: How to Avoid Design Choices That Generate Immortal Time. | Cancer Med | 2026 | https://conductscience.org/library/papers/42321955 | PubMed |
| 41974756 | A pipeline of machine learning-driven multi-modal data fusion methods for prognostic risk analysis in bevacizumab-treated metastatic colorectal cancer. | Sci Rep | 2026 | https://conductscience.org/library/papers/41974756 | PubMed |
| 41456238 | Immunohistochemical evaluation of EGFR protein expression and microvascular density reveals an angiogenic signature in Tunisian patients with metastatic colorectal cancer. | Clin Transl Oncol | 2026 | https://conductscience.org/library/papers/41456238 | PubMed |
| 40940901 | Anti-EGFR Therapy in Metastatic Colorectal Cancer: Identifying, Tracking, and Overcoming Resistance. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/40940901 | PubMed |
| 38944037 | Modulating cancer mechanopathology to restore vascular function and enhance immunotherapy. | Cell Rep Med | 2024 | https://conductscience.org/library/papers/38944037 | PubMed |
| 38811554 | Analysis of cell free DNA to predict outcome to bevacizumab therapy in colorectal cancer patients. | NPJ Genom Med | 2024 | https://conductscience.org/library/papers/38811554 | PubMed |
| 38775718 | Combining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer (ECOG-ACRIN E7208). | J Natl Cancer Inst | 2024 | https://conductscience.org/library/papers/38775718 | PubMed |
| 38254903 | Cetuximab as a Key Partner in Personalized Targeted Therapy for Metastatic Colorectal Cancer. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/38254903 | PubMed |
| 37456800 | KRAS mutations and their associations with clinicopathological features and survival in Vietnamese non‑polyp colon cancer patients. | Mol Clin Oncol | 2023 | https://conductscience.org/library/papers/37456800 | PubMed |
| 37409250 | Molecular and genetic targets within metastatic colorectal cancer and associated novel treatment advancements. | Front Oncol | 2023 | https://conductscience.org/library/papers/37409250 | PubMed |
| 36915460 | Using a combination of fruquintinib, raltitrexed, and S-1 as a third-line treatment for metastatic colorectal cancer with co-existence of Hodgkin lymphoma: a case report. | J Gastrointest Oncol | 2023 | https://conductscience.org/library/papers/36915460 | PubMed |
| 36578083 | KPNA2 promotes angiogenesis by regulating STAT3 phosphorylation. | J Transl Med | 2022 | https://conductscience.org/library/papers/36578083 | PubMed |
| 35380713 | Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial. | Oncologist | 2022 | https://conductscience.org/library/papers/35380713 | PubMed |
| 35261903 | Efficacy and safety of regorafenib and fruquintinib as third-line treatment for colorectal cancer: a narrative review. | Transl Cancer Res | 2022 | https://conductscience.org/library/papers/35261903 | PubMed |
| 35223449 | Efficacy and Safety of Systemic Treatments Among Colorectal Cancer Patients: A Network Meta-Analysis of Randomized Controlled Trials. | Front Oncol | 2021 | https://conductscience.org/library/papers/35223449 | PubMed |
| 34712608 | Knockdown of PPARδ Induces VEGFA-Mediated Angiogenesis via Interaction With ERO1A in Human Colorectal Cancer. | Front Oncol | 2021 | https://conductscience.org/library/papers/34712608 | PubMed |
| 34476218 | Vascular Normalization: A New Window Opened for Cancer Therapies. | Front Oncol | 2021 | https://conductscience.org/library/papers/34476218 | PubMed |
| 34446980 | Monitoring cancer cell surface receptor expression during anti-angiogenesis therapy in vivo. | Proc SPIE Int Soc Opt Eng | 2021 | https://conductscience.org/library/papers/34446980 | PubMed |
| 34109130 | Combination of Anti-EGFR and Anti-VEGF Drugs for the Treatment of Previously Treated Metastatic Colorectal Cancer: A Case Report and Literature Review. | Front Oncol | 2021 | https://conductscience.org/library/papers/34109130 | PubMed |
| 33868486 | Impact of EGFR and EGFR ligand expression on treatment response in patients with metastatic colorectal cancer. | Oncol Lett | 2021 | https://conductscience.org/library/papers/33868486 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/17876013
GET https://conductscience.org/api/papers/v1/17876013/cited_by?page=2